Drug-Induced Hypertrichosis: Case Report and Review of the Literature

Miwa, Linda J.; Shaefer, Mark S.; Stratta, Robert J.; Wood, R. P.; Langnas, A. M.; Shaw, Byers W.

doi:10.1177/106002809002400404

Cited by 13 publications

(6 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The acquired localized hypertrichosis (ALH) has been found to be associated with various factors such as chronic irritation, inflammation and friction, around the edges of a burn, and also with drugs such as topical steroid, minoxidil, and phenytoin. [ 7 8 ] It has been reported following varied procedures such as henna tattoos, sclerotherapy, and even subsiding psoriasis. [ 9 10 11 ] A mild form of ALH is usually observed after the plaster cast application.…”

Section: Discussionmentioning

confidence: 99%

Localized hypertrichosis at vaccination site

2018

View full text Add to dashboard Cite

Hypertrichosis is described as an increased hair growth on any part or over whole body in comparison to persons of the same age, sex, and race which is independent of androgen excess. It may be localized and generalized or alternatively acquired and congenital forms. The acquired localized hypertrichosis has been associated with various causes including local trauma, chronic irritation, inflammation, occlusion by cast, and drugs. Here, we report a case of 2½-month-old healthy infant presenting with localized area of hypertrichosis over anterolateral aspect of the left thigh which was confined to the site of vaccination.

show abstract

Section: Discussionmentioning

confidence: 99%

Localized hypertrichosis at vaccination site

2018

View full text Add to dashboard Cite

show abstract

“…Systemic administration of minoxidil either by oral administration to the mother during pregnancy or by oral ingestion by the child, has led to rarely reported instances of diffuse hypertrichosis in children 1, 2 and newborns via maternal–fetal transmission 3, 4 .…”

Section: Discussionmentioning

confidence: 99%

Minoxidil induced hypertrichosis in a 2 year-old child

2013

View full text Add to dashboard Cite

show abstract

“…We identified 14 studies (7 case reports, 5 cohort studies, and 2 case series) describing 42 patients utilizing an oral minoxidil dose of 3.0 to 15.0 mg daily [21][22][23][24][25][26][27][28][29][30][31][32][33][34]. For the purposes of this study, this dose will be classified as moderate-dose oral minoxidil (MDOM).…”

Section: Moderate-dose (26-15 Mg)mentioning

confidence: 99%

“…For the purposes of this study, this dose will be classified as moderate-dose oral minoxidil (MDOM). Of the 42 patients, oral minoxidil was used for the treatment of hypertension in 22 (52.3%) [21][22][23][24][25][26][27][28][29][30][32][33][34]. Twenty (47.7%) patients experienced a systemic accidental overdose when minoxidil was mistakenly replaced with omeprazole pills prior to dissemination [31].…”

Section: Moderate-dose (26-15 Mg)mentioning

confidence: 99%

Evaluation of the Safety and Effectiveness of Oral Minoxidil in Children: A Systematic Review

Williams,

Olukoga,

Tosti

2024

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

The minimal adverse-effect profile and positive clinical response of low-dose oral minoxidil (LDOM) have recently caused the drug to gain popularity for the treatment of hair disorders in adults. However, in the pediatric population, hesitancy still surrounds the use of oral minoxidil given the wide profile of potential side effects the drug offers. This review aims to characterize the safety and use of oral minoxidil in children for the treatment of all disorders to equip physicians with ample knowledge when prescribing oral minoxidil in the pediatric population. A total of 41 studies (19 case reports, 10 cohort studies, 7 retrospective chart reviews, and 5 case series) that reported data on 442 pediatric patients for whom oral minoxidil was used for treatment were included. Conditions for which treatment with minoxidil was described were hair disorders (83.9%, 371/442) and hypertension (11.3%, 50/442); accidental usage (4.8%, 21/442) was also noted in the literature and included in this review. This review is broken down by dosage and describes the safety and efficacy of oral minoxidil in pediatric patients aged 0 to 18 years old for the treatment of hair disorders. This review found that LDOM may represent a safe option for the treatment of hair disorders in children. This study also suggests moderate and high doses of oral minoxidil may not be safe for use in children. Additional studies are needed to further understand this drug’s efficacy and safety in children.

show abstract

Drug-Induced Hypertrichosis: Case Report and Review of the Literature

Cited by 13 publications

References 32 publications

Localized hypertrichosis at vaccination site

Localized hypertrichosis at vaccination site

Minoxidil induced hypertrichosis in a 2 year-old child

Evaluation of the Safety and Effectiveness of Oral Minoxidil in Children: A Systematic Review

Contact Info

Product

Resources

About